VKTX Quote, Financials, Valuation and Earnings

Hims & Hers Health, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 2.63%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 198.82%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $27.46 which suggests that it could grow by 75.68%. Given that Viking Therapeutics, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Hims & Hers Health, Inc..

Viking Therapeutics, Inc. has a beta of 0.755, which suggesting that the stock is 24.489% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.431, suggesting its more volatile than the S&P 500 by 143.147%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 28.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 1.75x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 34.4%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Eli Lilly & Co.'s return on equity of 104.39%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 198.82%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Viking Therapeutics, Inc. has a beta of 0.755, which suggesting that the stock is 24.489% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of -9.34%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Pfizer Inc.'s return on equity of 10.84%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 198.82%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 7.18%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Viking Therapeutics, Inc. has a beta of 0.755, which suggesting that the stock is 24.489% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.45% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Viking Therapeutics, Inc.'s net income of -$157.7M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 19.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 2.43x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 21.74%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 198.82%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Viking Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Viking Therapeutics, Inc. has a beta of 0.755, which suggesting that the stock is 24.489% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.